Search

Your search keyword '"le Coutre, Philipp"' showing total 184 results
Start Over Author "le Coutre, Philipp" Search Limiters Academic (Peer-Reviewed) Journals
184 results on '"le Coutre, Philipp"'

1. FRACTION: protocol of a phase II study of Fedratinib and Nivolumab combination in patients with myelofibrosis and resistance or suboptimal response to JAK-inhibitor treatment of the German MPN study group (GSG-MPN)

Author

Isfort, Susanne, von Bubnoff, Nikolas, Al-Ali, Haifa Kathrin, Becker, Heiko, Götze, Thorsten, le Coutre, Philipp, Griesshammer, Martin, Moskwa, Claudia, Wohn, Luisa, Riedel, Johanna, Palandri, Francesca, Manz, Kirsi, Hochhaus, Andreas, Döhner, Konstanze, and Heidel, Florian H.

Published
2024
Full Text
View/download PDF

2. Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up results

Author

Cortes, Jorge E., Sasaki, Koji, Kim, Dong-Wook, Hughes, Timothy P., Etienne, Gabriel, Mauro, Michael J., Hochhaus, Andreas, Lang, Fabian, Heinrich, Michael C., Breccia, Massimo, Deininger, Michael, Goh, Yeow Tee, Janssen, Jeroen J.W.M., Talpaz, Moshe, de Soria, Valle Gomez Garcia, le Coutre, Philipp, DeAngelo, Daniel J., Damon, Andrea, Cacciatore, Silvia, Polydoros, Fotis, Agrawal, Nithya, and Rea, Delphine

Published
2024
Full Text
View/download PDF

3. Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results

Author

Mauro, Michael J., Hughes, Timothy P., Kim, Dong-Wook, Rea, Delphine, Cortes, Jorge E., Hochhaus, Andreas, Sasaki, Koji, Breccia, Massimo, Talpaz, Moshe, Ottmann, Oliver, Minami, Hironobu, Goh, Yeow Tee, DeAngelo, Daniel J., Heinrich, Michael C., Gómez-García de Soria, Valle, le Coutre, Philipp, Mahon, Francois-Xavier, Janssen, Jeroen J. W. M., Deininger, Michael, Shanmuganathan, Naranie, Geyer, Mark B., Cacciatore, Silvia, Polydoros, Fotis, Agrawal, Nithya, Hoch, Matthias, and Lang, Fabian

Published
2023
Full Text
View/download PDF

4. Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL

Author

Hochhaus, Andreas, Réa, Delphine, Boquimpani, Carla, Minami, Yosuke, Cortes, Jorge E., Hughes, Timothy P., Apperley, Jane F., Lomaia, Elza, Voloshin, Sergey, Turkina, Anna, Kim, Dong-Wook, Abdo, Andre, Fogliatto, Laura Maria, le Coutre, Philipp, Sasaki, Koji, Kim, Dennis Dong Hwan, Saussele, Susanne, Annunziata, Mario, Chaudhri, Naeem, Chee, Lynette, García-Gutiérrez, Valentin, Kapoor, Shruti, Allepuz, Alex, Quenet, Sara, Bédoucha, Véronique, and Mauro, Michael J.

Published
2023
Full Text
View/download PDF

6. Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial

Author

Brümmendorf, Tim H., Cortes, Jorge E., Milojkovic, Dragana, Gambacorti-Passerini, Carlo, Clark, Richard E., le Coutre, Philipp, Garcia-Gutierrez, Valentin, Chuah, Charles, Kota, Vamsi, Lipton, Jeffrey H., Rousselot, Philippe, Mauro, Michael J., Hochhaus, Andreas, Hurtado Monroy, Rafael, Leip, Eric, Purcell, Simon, Yver, Anne, Viqueira, Andrea, and Deininger, Michael W.

Published
2022
Full Text
View/download PDF

7. Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial

Author

Radich, Jerald P., Hochhaus, Andreas, Masszi, Tamás, Hellmann, Andrzej, Stentoft, Jesper, Casares, María Teresa Gómez, García-Gutiérrez, J. Valentín, Conneally, Eibhlin, le Coutre, Philipp D., Gattermann, Norbert, Martino, Bruno, Saussele, Susanne, Giles, Francis J., Ross, David M., Aimone, Paola, Li, Sai, Titorenko, Ksenia, and Saglio, Giuseppe

Published
2021
Full Text
View/download PDF

8. Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis

Author

Kantarjian, Hagop M., Hughes, Timothy P., Larson, Richard A., Kim, Dong-Wook, Issaragrisil, Surapol, le Coutre, Philipp, Etienne, Gabriel, Boquimpani, Carla, Pasquini, Ricardo, Clark, Richard E., Dubruille, Viviane, Flinn, Ian W., Kyrcz-Krzemien, Slawomira, Medras, Ewa, Zanichelli, Maria, Bendit, Israel, Cacciatore, Silvia, Titorenko, Ksenia, Aimone, Paola, Saglio, Giuseppe, and Hochhaus, Andreas

Published
2021
Full Text
View/download PDF

9. Addendum to the German Consensus Recommendations on Ponatinib in the Treatment of Chronic Myeloid Leukemia.

Author

Saussele, Susanne, La Rosée, Paul, Kiani, Alexander, Haverkamp, Wilhelm, Jentsch-Ullrich, Kathleen, Stegelmann, Frank, Rieger, Christina, Waller, Cornelius F., Franke, Georg-Nikolaus, Junghanss, Christian, Kirchmair, Rudolf, Theurl, Markus, and le Coutre, Philipp

Subjects
CHRONIC myeloid leukemia, DECISION trees, CARDIOVASCULAR diseases
Abstract

Background: Based on the new data from the primary analysis of the OPTIC (Optimizing Ponatinib Treatment in CP-CML) trial on dose optimization of ponatinib in patients with chronic phase (CP)-CML, the German consensus paper on ponatinib published in 2020 (Saussele S et al., Acta Haematol. 2020) has been updated in this addendum. Summary: Focus is on the update of efficacy and safety of ponatinib, reflecting the new data set, as well as the update of the benefit-risk assessment and recommendations for ponatinib starting dose in CP-CML – provided that the decision to use ponatinib has already been made. Furthermore, based on OPTIC and additional empirical data, the expert panel collaborated to develop a decision tree for ponatinib dosing, specifically for intolerant and resistant patients. The recommendations on cardiovascular management have also been updated based on the most recent 2021 guidelines of the European Society of Cardiology (ESC) on cardiovascular disease prevention in clinical practice. Key Messages: The OPTIC data confirm the high efficacy of ponatinib in patients with CP-CML and provide the basis for individualized dose adjustment during the course of treatment. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

10. Physical exercise recommendations for patients with chronic myeloid leukemia based on individual preferences identified in a large international patient survey study of the East German Study Group for Hematology and Oncology (OSHO #97).

Author

Hollenbach, Lina, Rogahn, Julia, le Coutre, Philipp, Schulze, Susann, Muegge, Lars-Olof, Geissler, Jan, Gruen, Julia, Junghanss, Christian, and Felser, Sabine

Subjects
CHRONIC myeloid leukemia, SUNBURN, SKIN cancer, PATIENT surveys, SWIMMING pools, MYELOPROLIFERATIVE neoplasms, PROTEIN-tyrosine kinase inhibitors
Abstract

Background: Tyrosine kinase inhibitors (TKIs) have significantly lowered mortality of chronic myeloid leukemia (CML) patients adjusting life expectancy to that of the standard population. However, CML and its treatment with TKIs causes a high disease burden. Physical exercise (PE) could be a non-pharmacological approach to reducing these and improving quality of life. Purpose: The aim of this study was to determine the individual disease burden as well as PE preferences of CML patients and to deduce thereof specific PE recommendations. Methods: This multicenter survey was conducted in cooperation with the LeukaNET/Leukemia-patient network including CML patients aged =18 years (German Registry of Clinical Trials, DRKS00023698). The severity of selected symptoms was assessed using the adapted Myeloproliferative Neoplasms Symptom Assessment Form: 0 (absent), 1-30 (mild), 31-70 (moderate), or 71-100 (severe). Information about patients' PE needs and preferences depending on their motivation was recorded. Results: A total of 212 questionnaires were analyzed (52% female, median age 54 years). The prevalence of moderate-to-severe symptoms was 49% for fatigue, 40% for musculoskeletal pain, and 37% for concentration problems. Other commonly reported symptoms included skin reactions (42%) and weight gain (24%). The proportion of overweight/obese patients was 52%. Half of all respondents requested more information regarding PE. Patients with CML preferred individual training (82%), located outdoors (71%), at home (47%), or in an indoor swimming pool (31%). Regarding the training frequency, sportsinactive patients preferred a frequency of 1-2 training sessions per week, whereas sports-active patients preferred 3-4 sessions per week (p <0.001). Sports-inactive patients preferred a training time of 15-45 minutes, while sports-active patients preferred 30-60 minutes (p = 0.002). Subsequently, PE recommendations were developed for patients with CML. Combined resistance and endurance training (moderate intensity twice per week for 30 minutes) was recommended for beginners. Obese patients should prioritize joint-relieving sports. To reduce the risk of skin reactions, direct sunlight and possibly water sports should be avoided, and UV protection should be used. Conclusion: Counseling and motivation of CML patients to be physically active should be part of the standard of care as well as support for implementation. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

11. VEXAS and Myelodysplastic Syndrome: An Interdisciplinary Challenge.

Author

Kreutzinger, Virginie, Pankow, Anne, Boyadzhieva, Zhivana, Schneider, Udo, Ziegeler, Katharina, Stephan, Lars Uwe, Kübke, Jan Carl, Schröder, Sebastian, Oberender, Christian, le Coutre, Philipp, Stintzing, Sebastian, and Jelas, Ivan

Subjects
MYELODYSPLASTIC syndromes, SOMATIC mutation, BLOOD diseases, SYMPTOMS, THERAPEUTICS
Abstract

VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is a recently recognized systemic autoinflammatory disease caused by somatic mutations in hematopoietic progenitor cells. This case series of four patients with VEXAS syndrome and comorbid myelodysplastic syndrome (MDS) aims to describe clinical, imaging, and hematologic disease presentations as well as response to therapy. Four patients with VEXAS syndrome and MDS are described. A detailed analysis of imaging features, hemato-oncological presentation including bone marrow microscopy and clinical–rheumatological disease features and treatment outcomes is given. All patients were male; ages ranged between 64 and 81 years; all were diagnosed with MDS. CT imaging was available for three patients, all of whom exhibited pulmonary infiltrates of varying severity, resembling COVID-19 or hypersensitivity pneumonitis without traces of scarring. Bone marrow microscopy showed maturation-disordered erythropoiesis and pathognomonic vacuolation. Somatic mutation in the UBA1 codon 41 were found in all patients by next-generation sequencing. Therapy regimes included glucocorticoids, JAK1/2-inhibitors, nucleoside analogues, as well as IL-1 and IL-6 receptor antagonists. No fatalities occurred (observation period from symptom onset: 18–68 months). Given the potential underreporting of VEXAS syndrome, we highly recommend contemporary screening for UBA1 mutations in patients presenting with ambiguous signs of systemic autoinflammatory symptoms which persist over 18 months despite treatment. The emergence of cytopenia, especially macrocytic hyperchromic anemia, should prompt early testing for UBA1 mutations. Notably conspicuous, pulmonary alterations in CT imaging of patients with therapy-resistant systemic autoinflammatory symptoms should be discussed in interdisciplinary medical teams (Rheumatology, Hematology, Radiology and further specialist departments) to facilitate timely diagnosis during the clinical course of the disease. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

12. Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trial

Author

Cortes, Jorge E., Kim, Dong-Wook, Pinilla-Ibarz, Javier, le Coutre, Philipp D., Paquette, Ronald, Chuah, Charles, Nicolini, Franck E., Apperley, Jane F., Khoury, H. Jean, Talpaz, Moshe, DeAngelo, Daniel J., Abruzzese, Elisabetta, Rea, Delphine, Baccarani, Michele, Müller, Martin C., Gambacorti-Passerini, Carlo, Lustgarten, Stephanie, Rivera, Victor M., Haluska, Frank G., Guilhot, François, Deininger, Michael W., Hochhaus, Andreas, Hughes, Timothy P., Shah, Neil P., and Kantarjian, Hagop M.

Published
2018
Full Text
View/download PDF

14. Patient-reported outcomes in the phase 3 BFORE trial of bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia

Author

Cortes, Jorge E., Gambacorti-Passerini, Carlo, Deininger, Michael W., Mauro, Michael J., Chuah, Charles, Kim, Dong-Wook, Milojkovic, Dragana, le Coutre, Philipp, Garcia-Gutierrez, Valentin, Crescenzo, Rocco, Mamolo, Carla, Reisman, Arlene, Hochhaus, Andreas, Brümmendorf, Tim H., and the BFORE Study Investigators

Published
2019
Full Text
View/download PDF

15. Single-cell analysis based dissection of clonality in myelofibrosis

Author

Mylonas, Elena, Yoshida, Kenichi, Frick, Mareike, Hoyer, Kaja, Christen, Friederike, Kaeda, Jaspal, Obenaus, Matthias, Noerenberg, Daniel, Hennch, Cornelius, Chan, Willy, Ochi, Yotaro, Shiraishi, Yuichi, Shiozawa, Yusuke, Zenz, Thorsten, Oakes, Christopher C., Sawitzki, Birgit, Schwarz, Michaela, Bullinger, Lars, le Coutre, Philipp, Rose-Zerilli, Matthew J. J., Ogawa, Seishi, and Damm, Frederik

Published
2020
Full Text
View/download PDF

17. Risk of progression in chronic phase‐chronic myeloid leukemia patients eligible for tyrosine kinase inhibitor discontinuation: Final analysis of the TFR‐PRO study.

Author

Zambrotta, Giovanni Paolo Maria, Nicolini, Franck E., Assouline, Sarit, Busque, Lambert, Pungolino, Ester, Abruzzese, Elisabetta, Miggiano, Maria Cristina, Elena, Chiara, Alvarez‐Larran, Alberto, Triguero, Ana, Iurlo, Alessandra, Bucelli, Cristina, Cerrano, Marco, Capodanno, Isabella, Lunghi, Francesca, le Coutre, Philipp, Galimberti, Sara, Caocci, Giovanni, Maffioli, Margherita, and Stagno, Fabio

Published
2023
Full Text
View/download PDF

18. Switching to nilotinib versus imatinib dose escalation in patients with chronic myeloid leukaemia in chronic phase with suboptimal response to imatinib (LASOR): a randomised, open-label trial

Author

Cortes, Jorge E, De Souza, Carmino Antonio, Ayala, Manuel, Lopez, Jose Luis, Bullorsky, Eduardo, Shah, Sandip, Huang, Xiaojun, Babu, K Govind, Abdulkadyrov, Kudrat, de Oliveira, José Salvador Rodrigues, Shen, Zhi-Xiang, Sacha, Tomasz, Bendit, Israel, Liang, Zhizhou, Owugah, Tina, Szczudlo, Tomasz, Khanna, Sadhvi, Fellague-Chebra, Rafik, and le Coutre, Philipp D

Published
2016
Full Text
View/download PDF

19. Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia

Author

Kreitman, Robert J., Dearden, Claire, Zinzani, Pier Luigi, Delgado, Julio, Karlin, Lionel, Robak, Tadeusz, Gladstone, Douglas E., le Coutre, Philipp, Dietrich, Sascha, Gotic, Mirjana, Larratt, Loree, Offner, Fritz, Schiller, Gary, Swords, Ronan, Bacon, Larry, Bocchia, Monica, Bouabdallah, Krimo, Breems, Dimitri A., Cortelezzi, Agostino, Dinner, Shira, Doubek, Michael, Gjertsen, Bjorn Tore, Gobbi, Marco, Hellmann, Andrzej, Lepretre, Stephane, Maloisel, Frederic, Ravandi, Farhad, Rousselot, Philippe, Rummel, Mathias, Siddiqi, Tanya, Tadmor, Tamar, Troussard, Xavier, Yi, Cecilia Arana, Saglio, Giuseppe, Roboz, Gail J., Balic, Kemal, Standifer, Nathan, He, Peng, Marshall, Shannon, Wilson, Wyndham, Pastan, Ira, Yao, Nai-Shun, and Giles, Francis

Published
2018
Full Text
View/download PDF

20. Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study

Author

Ross, David M., Masszi, Tamas, Gómez Casares, María Teresa, Hellmann, Andrzej, Stentoft, Jesper, Conneally, Eibhlin, Garcia-Gutierrez, Valentin, Gattermann, Norbert, le Coutre, Philipp D., Martino, Bruno, Saussele, Susanne, Giles, Francis J., Radich, Jerald P., Saglio, Giuseppe, Deng, Weiping, Krunic, Nancy, Bédoucha, Véronique, Gopalakrishna, Prashanth, and Hochhaus, Andreas

Published
2018
Full Text
View/download PDF

21. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial

Author

Lipton, Jeffrey H, Chuah, Charles, Guerci-Bresler, Agnès, Rosti, Gianantonio, Simpson, David, Assouline, Sarit, Etienne, Gabriel, Nicolini, Franck E, le Coutre, Philipp, Clark, Richard E, Stenke, Leif, Andorsky, David, Oehler, Vivian, Lustgarten, Stephanie, Rivera, Victor M, Clackson, Timothy, Haluska, Frank G, Baccarani, Michele, Cortes, Jorge E, Guilhot, François, Hochhaus, Andreas, Hughes, Timothy, Kantarjian, Hagop M, Shah, Neil P, Talpaz, Moshe, and Deininger, Michael W

Published
2016
Full Text
View/download PDF

22. The Recurrent Atypical e8a2 BCR::ABL1 Transcript with Insertion of an Inverted 55 Base Pair ABL1 Intron 1b Sequence: A Detailed Molecular Analysis.

Author

Burmeister, Thomas, Bullinger, Lars, and le Coutre, Philipp

Subjects
BASE pairs, CHRONIC myeloid leukemia, PROTEIN-tyrosine kinase inhibitors, CHROMOSOMAL translocation, CHRONIC leukemia
Abstract

Atypical BCR::ABL1 transcripts are found in approximately 2% of cases of chronic myeloid leukemia. It is important to detect them since affected patients also benefit from tyrosine kinase inhibitor therapy. In the rare e8a2 atypical BCR::ABL1 transcript, two out-of-frame exons are fused, thus, interposed nucleotides are usually found at the fusion site to restore the reading frame. In approximately half of previously reported e8a2 BCR::ABL1 cases, an inserted 55 bp sequence homologous to an inverted sequence from ABL1 intron 1b was detected. The generation of this recurrent transcript variant is not obvious. This work describes the molecular analysis of such an e8a2 BCR::ABL1 translocation from a CML patient. The genomic chromosomal breakpoint is identified, and the formation of this transcript is theoretically explained. The clinical course of the patient is reported, and recommendations are provided for the molecular analysis of future e8a2 BCR::ABL1 cases. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

23. Physical exercise recommendations for patients with polycythemia vera based on preferences identified in a large international patient survey study of the East German Study Group for Hematology and Oncology (OSHO #97).

Author

Felser, Sabine, Rogahn, Julia, Hollenbach, Lina, Gruen, Julia, le Coutre, Philipp, Al‐Ali, Haifa Kathrin, Schulze, Susann, Muegge, Lars‐Olof, Kraze‐Kliebhahn, Veronika, and Junghanss, Christian

Subjects
POLYCYTHEMIA vera, PATIENT surveys, EXERCISE therapy, MYELOPROLIFERATIVE neoplasms, HEMATOLOGY, MYELOFIBROSIS, POSTPOLIOMYELITIS syndrome
Abstract

Background: Exercise therapy during cancer treatment reduces symptom burden and improves quality of life (QoL). Polycythemia vera (PV) is a myeloproliferative neoplasia associated with good overall survival (up to decades) but a significant symptom burden, including thromboembolic events and dysesthesias. There are no specific exercise recommendations for patients with PV. Thus, we aimed to determine the exercise preferences of patients with PV and to derive specific recommendations based on the most commonly reported symptoms. Methods: This multicenter survey included patients with PV ≥18 years old. Demographic, clinical, and disease burden data were collected. The severity of selected symptoms was assessed using the adapted Myeloproliferative Neoplasms Symptom Assessment Form: 0 (absent), 1–30 (mild), 31–70 (moderate), or 71–100 (severe). The patients' information needs about physical activity (PA) and exercise preferences were recorded depending on their motivation and analyzed with regard to demographic aspects. Results: The sample comprised 182 patients (68% female, 61 ± 12 years). The prevalence of moderate‐to‐severe symptoms was 60% for fatigue, 44% for concentration problems, and 35% for bone/muscle pain. Other commonly reported symptoms included skin reactions (49%), splenomegaly (35%), and increased bleeding tendency (28%). Overall, 67% of respondents requested more information regarding PA. Patients with PV preferred individual training (79%) located outdoors (79%) or at home (56%). Regarding the amount of training, sports‐inactive patients preferred a frequency of 1–2 times/week and session durations of 15–45 min, whereas sports‐active patients preferred 3–4 times/week and 30–60 min (p < 0.001). Higher sport‐inactiveness was observed in patients with lower educational level compared to patients with higher educational level (69% vs. 50%, p = 0.021). For beginners, combined resistance‐endurance (circuit) training two times/week, which can be performed outdoors or at home, should be recommended. In the case of splenomegaly or bleeding symptoms, exercises with a low injury risk should be chosen. Conclusion: PA is important for patients with PV; therefore, counseling should be integrated into the treatment plan. Specifically, patients with low educational level should be addressed. Prospective studies are warranted to evaluate the effects of the novel exercise recommendations. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

24. Variable Outcomes of Hepatitis E Infections in Patients with Hemato-Oncologic Diseases.

Author

Ingwersen, Viktoria, Hofmann, Jörg, Muche, Marion, Le Coutre, Philipp, Schneider, Thomas, Leng, Corinna, Burmeister, Thomas, Maschmeyer, Georg, Keller, Ulrich, and Schwartz, Stefan

Subjects
HEPATITIS E, HEPATITIS C, LYMPHOPENIA, HEMATOPOIETIC stem cell transplantation, HEPATITIS E virus, T-cell exhaustion, VIRAL hepatitis
Abstract

Introduction: The hepatitis E virus (HEV) represents an important cause of viral hepatitis and could cause chronic infections in immunocompromised patients. However, data about immunocompromised patients other than solid organ transplant recipients are limited. Methods: We identified patients from a laboratory database and retrospectively compiled and analyzed clinical as well as laboratory data in detail. Results: Overall, 22 severely immunosuppressed patients, excluding solid organ transplant recipients, were identified. Four patients did not experience viral clearance (one without and three despite ribavirin therapy). Three patients acquired the infection after allogeneic hematopoietic stem cell transplantation (alloHSCT) and recovered spontaneously, whereas another patient, infected prior to alloHSCT, developed a chronic infection. Four patients failed to clear HEV, resulting in fatal liver failure in 2 patients. The CD4+ cell counts increased in all but 1 patient attaining a sustained virological response (SVR), as compared to patients with clinical failure. Severe immunoglobulin deficiency did not appear to obviate the control of HEV. Six of ten (60%) patients with and nine of 12 (75%) patients without ribavirin therapy achieved an SVR. Conclusions: Upfront ribavirin therapy does not appear mandatory in patients without CD4+ lymphopenia, but a prolonged HEV replication carries the risk of liver failure. Our data suggest that chronic HEV infections could cause T-cell exhaustion, which might be overruled with ribavirin therapy. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

27. Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis

Author

Giles, Francis J., Rea, Delphine, Rosti, Gianantonio, Cross, Nicholas C. P., Steegmann, Juan Luis, Griskevicius, Laimonas, le Coutre, Philipp, Coriu, Daniel, Petrov, Ljubomir, Ossenkoppele, Gert J., Mahon, Francois-Xavier, Saussele, Susanne, Hellmann, Andrzej, Koskenvesa, Perttu, Brümmendorf, Tim H., Gastl, Gunther, Castagnetti, Fausto, Vincenzi, Beatrice, Haenig, Jens, and Hochhaus, Andreas

Published
2017
Full Text
View/download PDF

28. Nilotinib first-line therapy in patients with Philadelphia chromosome-negative/BCR-ABL-positive chronic myeloid leukemia in chronic phase: ENEST1st sub-analysis

Author

Hochhaus, Andreas, Mahon, Franҫois-Xavier, le Coutre, Philipp, Petrov, Ljubomir, Janssen, Jeroen J. W. M., Cross, Nicholas C. P., Rea, Delphine, Castagnetti, Fausto, Hellmann, Andrzej, Rosti, Gianantonio, Gattermann, Norbert, Coronel, Maria Liz Paciello, Gutierrez, Maria Asuncion Echeveste, Garcia-Gutierrez, Valentin, Vincenzi, Beatrice, Dezzani, Luca, and Giles, Francis J.

Published
2017
Full Text
View/download PDF

35. Anxieties, age and motivation influence physical activity in patients with myeloproliferative neoplasms - a multicenter survey from the East German study group for hematology and oncology (OSHO #97).

Author

Felser, Sabine, Rogahn, Julia, le Coutre, Philipp, Kathrin Al-Ali, Haifa, Schulze, Susann, Muegge, Lars-Olof, Gruen, Julia, Geissler, Jan, Kraze-Kliebhahn, Veronika, and Junghanss, Christian

Subjects
MYELOPROLIFERATIVE neoplasms, PHYSICAL activity, QUALITY of life, ANXIETY, MOTIVATION (Psychology), PSYCHO-oncology
Abstract

Background: Physical activity (PA) is a non-pharmacological approach to alleviate symptom burden and improve health-related quality of life (HrQoL) in cancer patients (pts). Whether pts with myeloproliferative neoplasms (MPN) PA behavior changes due to symptom burden and/or knowledge of the putative beneficial effects of PA has not yet been investigated. Methods: We performed a large questionnaire study in MPN pts. Self-reported PA behavior and potential influencing factors of 634 MPN pts were analyzed. Questionnaires were used to assess demographics, anxiety, severity of symptoms, HrQoL, current level of everyday and sports activities, and the level of information regarding the importance/possibilities of PA. According to their PA, the pts were assigned to the three groups: "inactive", "non-targeted active", and "sporty active" and compared with each other. Results: Key findings are that in 73% of the pts, the disease had an impact on PA, with 30% of pts reducing their PA. The prevalence of anxieties (e.g., occurrence of thrombosis and bleeding) regarding PA was 45%. Sporty active pts had a lower symptom burden and better HrQoL (p ≤ 0.001) compared to the other groups. Inactive pts were significantly older and had a higher body mass index than sporty active pts. Inactive and non-targeted active pts felt less informed about the importance/possibilities of PA (p = 0.002). Conclusion: Our results suggest that especially older and non-sporty MPN pts could benefit from motivational as well as disease-specific PA information. This study was registered at the German Registry of Clinical Trials, DRKS00023698. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

37. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results

Author

Kantarjian, Hagop M., Giles, Francis J., Bhalla, Kapil N., Pinilla-Ibarz, Javier, Larson, Richard A., Gattermann, Norbert, Ottmann, Oliver G., Hochhaus, Andreas, Radich, Jerald P., Saglio, Giuseppe, Hughes, Timothy P., Martinelli, Giovanni, Kim, Dong-Wook, Shou, Yaping, Gallagher, Neil J., Blakesley, Rick, Baccarani, Michele, Cortes, Jorge, and le Coutre, Philipp D.

Published
2011
Full Text
View/download PDF

41. Age and dPCR can predict relapse in CML patients who discontinued imatinib: The ISAV study

Author

Mori, Silvia, Vagge, Elisabetta, le Coutre, Philipp, Abruzzese, Elisabetta, Martino, Bruno, Pungolino, Ester, Elena, Chiara, Pierri, Ivana, Assouline, Sarit, DʼEmilio, Anna, Gozzini, Antonella, Giraldo, Pilar, Stagno, Fabio, Iurlo, Alessandra, Luciani, Michela, De Riso, Giulia, Redaelli, Sara, Kim, Dong-Wook, Pirola, Alessandra, Mezzatesta, Caterina, Petroccione, Anna, DʼOria, Agnese Lodolo, Crivori, Patrizia, Piazza, Rocco, and Gambacorti-Passerini, Carlo

Published
2015
Full Text
View/download PDF

47. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia

Author

le Coutre, Philipp, Ottmann, Oliver G., Giles, Francis, Kim, Dong-Wook, Cortes, Jorge, Gattermann, Norbert, Apperley, Jane F., Larson, Richard A., Abruzzese, Elisabetta, O'Brien, Stephen G., Kuliczkowski, Kazimierz, Hochhaus, Andreas, Mahon, Francois-Xavier, Saglio, Giuseppe, Gobbi, Marco, Kwong, Yok-Lam, Baccarani, Michele, Hughes, Timothy, Martinelli, Giovanni, Radich, Jerald P., Zheng, Ming, Shou, Yaping, and Kantarjian, Hagop

Published
2008
Full Text
View/download PDF

49. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia

Author

Saglio, Guiseppe, Haque, Ariful, Larson, Richard A., Kantarjian, Hagop M., Gallagher, Neil, Mei Dong, Hoenekopp, Albert, Clark, Richard E., Hochhaus, Andreas, Hughes, Timothy P., Etienne, Gabriel, Lobo, Clarisse, Pasquini, Ricardo, Dong-Wook Kim, Issaragrisil, Surapol, and le Coutre, Philipp

Subjects
Chronic myeloid leukemia -- Drug therapy, Nilotinib -- Safety and security measures, Nilotinib -- Comparative analysis, Antiviral agents -- Safety and security measures, Antiviral agents -- Comparative analysis
Abstract

A study was conducted to evaluate and compare the efficacy and safety of nilotinib as against imatinib for the treatment of newly diagnosed chronic myeloid leukemia. Results indicated that nilotinib at a dosage of 300 mg or 400 mg twice a day was found to be far more effective in the treatment of such patients.

Published
2010

Catalog

Books, media, physical & digital resources
See catalog results